In the interview ahead of the company’s de-SPAC, CEO also shared about the challenges and opportunities as the precision oncology space, the company’s immediate plan following its listing. He also shared his views on the biotech landscape in Southeast Asia and gave several suggestions for for companies, governments, and investors for the biotech industry in Southeast Asia.